Health issues affect many people as they age requiring them to move into assisted-care facilities where they are monitored by heath care professionals.
Dexcom G4 system that monitors glucose in a continuous manner has received CE Mark approval. The CE Mark approval enables commercialization of the G4 system in countries such as Latin America and Asia that recognize this CE Mark approval.
Sensirion have introduced their new SFM3000 mass flow meter for high-volume applications in medical devices, process automation and burner control. The flow channel is designed to achieve a very low pressure drop of less than 3mbar through the sensor element.
TactiCath Quartz force-sensing ablation catheter developed by Endosense has obtained a CE mark approval.
Nonin Medical declared that its EQUANOX Advance Model 7600 Cerebral/Somatic Oximetry System was one of the 20 products displayed at Premier healthcare alliance's Innovation Celebration in Nashville, Tennessee.
Nonin Medical has introduced the EQUANOX Advance Model 8004CB Series neonatal/pediatric sensor for the U.S. market.
JDRF together with BD (Becton, Dickinson and Company) recently declared that its present collaboration related to Type 1 diabetes (T1D) will be extended to promote expedite the development of the proprietary glucose-sensing technology of BD that precisely presents consistent glucose information.
So far, artificial noses are found to be effective in detecting diseases like tuberculosis, urinary tract infection, Helicobacter pylori, lung cancer in addition to ear, nose and throat severities. Following clinical tests, the artificial noses are now being used for continuous monitoring of various stages of disease.
JDRF along with the Helmsley Charitable Trust has partnered with Medtronic for the JDRF-HCT Sensor Initiative, which is targeted at continuous glucose monitoring (CGM) precision and consistency for sophisticated artificial pancreas systems.
Prostate cancer is the second leading cause of cancer mortalities in men. It is a malignant tumour, which generally affects men over 50, and the chance of diagnosing a prostate cancer is minimal. Survival mostly depends on the stage at which the cancer is detected. Now, new techniques have been developed that largely depend on an electronic nose and optoacoustics. These techniques can help improve diagnosis and prevent treatment delays.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.